Waters Corporation Reports Second Quarter 2025 Financial Results

Details

GAAP EPS was $2.47, and non-GAAP EPS was $2.95, both above mid-point of guidance. The company raised its full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and its non-GAAP EPS guidance to $12.95 to $13.05. The results reflect strong execution, rapid uptake of new products, and contribution from GLP-1s, PFAS, and generics.

Items reported

Exhibits (1)

About Waters Corporation

Waters Corporation is a leading entity in the field of analytical instruments and software. It primarily focuses on providing laboratory solutions for a variety of sectors, including pharmaceuticals, healthcare, food and beverage, and chemical analysis. The company's offerings include high-performance liquid chromatography, mass spectrometry systems, and various supporting technologies used for advanced research in life sciences. Waters Corporation is pivotal in enhancing laboratory productivity, offering cutting-edge research tools that assist in drug development, quality control, and environmental testing. Operating globally, it serves a wide array of clients, including academic institutions, government agencies, and private industry players. With its commitment to innovation and precision, Waters Corporation plays a crucial role in advancing scientific and technological progress in multiple critical industries worldwide.